During this one-on-one interview, Michael A. Evans, BS, RPh, of Geisinger Health System, discusses the use of warfarin as a treatment and/or prevention option for thromboembolic complications and explains why management of patients on warfarin is difficult.
Warfarin therapy, explains Mr Evans, requires frequent monitoring as warfarin is associated with numerous food interactions, drug-drug interactions, and disease interactions. Mr Evans also discusses warfarin’s mechanism of action and highlights specific foods, drugs, and conditions that affect the efficacy and safety of warfarin therapy.
Some patients prefer the frequent monitoring required with warfarin therapy, as it means more contact with healthcare providers; however, frequent visits for laboratory testing and monitoring place a burden on the healthcare system. As models of healthcare delivery change, patient access to care will become more challenging, says Mr Evans.
The number of testing and monitoring visits associated with warfarin therapy can potentially be reduced through the use of home INR monitoring devices, which allow patients to self-test and provide test results to their monitoring clinicians. However, the use of home INR monitoring devices is still resource utilization—intensive, notes Mr Evans.
The recent approval of direct-acting oral anticoagulants can benefit patient and clinicians, as these agents do not require routine monitoring, adds Mr Evans.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Health Equity and Access Weekly Roundup: April 27, 2024
April 27th 2024Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More